Literature DB >> 9157123

Comparison of Etest and agar dilution method for antimicrobial susceptibility testing of Flavobacterium isolates.

P R Hsueh1, J C Chang, L J Teng, P C Yang, S W Ho, W C Hsieh, K T Luh.   

Abstract

The Etest was evaluated as a possible alternative to the standard agar dilution method for susceptibility testing of nine antimicrobial agents against Flavobacterium species. In studies of 100 clinical isolates, the agreement between the MICs (+/-1 log2 dilution) obtained by the two methods was acceptable for cefotaxime, ceftazidime, amikacin, minocycline, ofloxacin, and ciprofloxacin (> 90%). Conversely, the agreement between the results obtained for piperacillin was limited (84%). The overall agreement was 92.5%.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9157123      PMCID： PMC229728          DOI： 10.1128/jcm.35.4.1021-1023.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  Evaluation of the E test, a novel method of quantifying antimicrobial activity.

Authors:  D F Brown; L Brown
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

2.  Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.

Authors:  C N Baker; S A Stocker; D H Culver; C Thornsberry
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 3.  Fatal pneumonia caused by Flavobacterium meningosepticum.

Authors:  A Y Tam; R W Yung; K H Fu
Journal:  Pediatr Infect Dis J       Date:  1989-04       Impact factor: 2.129

4.  Flavobacterium indologenes bacteremia: clinical and microbiological characteristics.

Authors:  P R Hsueh; T R Hsiue; J J Wu; L J Teng; S W Ho; W C Hsieh; K T Luh
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

5.  In-vitro sensitivity of Elavobacterium meningosepticum to antimicrobial agents.

Authors:  G Altmann; B Bogokovsky
Journal:  J Med Microbiol       Date:  1971-05       Impact factor: 2.472

6.  Flavobacterium group IIb bacteremia: report of a case and review of Flavobacterium infections.

Authors:  Y Siegman-Igra; D Schwartz; G Soferman; N Konforti
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

7.  Flavobacterium meningosepticum.

Authors:  H Ratner
Journal:  Infect Control       Date:  1984-05

8.  Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  Activities of aztreonam and new cephalosporins against infrequently isolated gram-negative bacilli.

Authors:  D A Strandberg; J H Jorgensen; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

Review 10.  In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents.

Authors:  R J Fass; J Barnishan
Journal:  Rev Infect Dis       Date:  1980 Nov-Dec
View more
  3 in total

1.  Community-acquired meningitis and sepsis caused by Chryseobacterium meningosepticum in a patient diagnosed with thalassemia major.

Authors:  Nisel Ozkalay; Murat Anil; Neval Agus; Mehmet Helvaci; Seral Sirti
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Reliability of Disk Diffusion Test Results for the Antimicrobial Susceptibility Testing of Nosocomial Gram-positive Microorganisms: Is E-test Method Better?

Authors:  Hossein Khalili; Rasool Soltani; Sorrosh Negahban; Alireza Abdollahi; Keirollah Gholami
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

3.  Antimicrobial susceptibility pattern of extended-spectrum β-lactamase-producing bacteria causing nosocomial urinary tract infections in an Iranian referral teaching hospital.

Authors:  Rasool Soltani; Mohsen Ehsanpoor; Farzin Khorvash; Dariush Shokri
Journal:  J Res Pharm Pract       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.